Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (384)
- Scheduling (national classification system) (181)
- Safety monitoring and information (33)
- COVID-19 (11)
- Manufacturing (10)
- Advertising (9)
- Clinical trials (9)
- Compliance and enforcement (6)
- Medicinal cannabis hub (6)
- Sunscreens (6)
- Fees and payments (5)
- Shortages and supply disruptions (4)
- Legislation (3)
- Breast implant hub (1)
- Import and export (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
784 result(s) found, displaying 1 to 25
-
Meeting statementsCommunique from the 7th meeting of the HREC Committee and TGA Clinical Trials Discussion Forum
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - ACCS and Joint ACMS-ACCS meetings - March 2025
-
Corporate reportsOutcomes of the review of digital scribes supplied in Australia.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 30 July 2026
-
Meeting statementsOutcomes following the Australian Influenza Vaccine Committee meeting held on Wednesday 7 October 2026.
-
TGA laboratory testing reportsImmunoglobulins, commonly known as antibodies, are specialised glycoproteins produced by plasma cells in response to the presence of antigens – foreign substances such as viruses, bacteria, or toxins.
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulation 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Meeting statementsCommunique from the Special Roundtable Discussion meeting with the Hon Rebecca White MP, 19 August 2026.
-
Corporate reportsWe conducted a safety review of 4-Methylbenzylidene camphor (4-MBC), an active ingredient in therapeutic sunscreens.
-
TGA laboratory testing reportsTGA Laboratories has released a report describing our assessment of the 2026 seasonal flu vaccine
-
Corporate reportsRead our business plan 2026-27 to find out about our strategic priorities and activities.
-
Meeting statementsCommunique from the 13th meeting of the Women's Health Products Working Group, 16 July 2026.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - ACCS and Joint ACMS-ACCS meetings - March 2025
-
Scheduling decisions (final)This web publication constitutes a notice for amendments to the current Poisons Standard made under section 52D(2) of the Therapeutic Goods Act 1989
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #47 meeting held in June 2025
-
Meeting statementsCommunique from the 6th meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 14 July 2026.
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #47 and Joint ACMS-ACCS #40 meetings held in June 2025
-
Corporate reportsDocuments released under the FOI Act in the 2025/26 financial year
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Corporate reportsThis Cost Recovery Implementation Statement (CRIS) 2026-2027 provides information on how we implement, and cost recover our regulatory activities.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 26 March 2026
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsCommunique from the 5th meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 13 April 2026.
-
Scheduling decisions (interim)Interim decisions and invitation for comment. Closing date: 10 July 2026.